(AEMD) Aethlon Medical - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00808Y3071
AEMD: Immunotherapeutic Devices, Medical Filters, Cancer Therapies
Aethlon Medical, Inc. is a medical technology company specializing in the development of innovative therapeutic devices designed to address life-threatening conditions, including cancer and infectious diseases. The companys flagship product, Hemopurifier, is a first-of-its-kind biofiltration platform intended to remove cancer-promoting exosomes and other harmful particles from the blood. This technology is being explored for its potential in treating various cancers, viral infections, and as a supportive measure in organ transplantation procedures. Headquartered in San Diego, California, Aethlon Medical has been at the forefront of medical innovation since its inception in 1984.
Based on the provided data, Aethlon Medicals stock (NASDAQ:AEMD) is expected to face challenges in the next three months. Technically, the stock is in a bearish trend as the price ($0.45) is below both the 20-day ($0.55) and 50-day ($0.64) moving averages. The 200-day moving average ($0.48) further indicates a downward trajectory. The average true range (ATR) of $0.06 suggests low volatility, which may limit significant price movements. From a fundamental perspective, the companys market capitalization of $6.50M reflects its micro-cap status, which often correlates with higher investment risk. The forward P/E ratio of 0.21 indicates potential undervaluation, but the negative return on equity (-0.22) raises concerns about profitability. The price-to-book ratio of 1.67 suggests the stock may be fairly valued relative to its book value, though the price-to-sales ratio of 2.37 points to a premium compared to its revenue generation. Overall, while there may be opportunities for long-term growth, short-term stability appears uncertain.
Additional Sources for AEMD Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AEMD Stock Overview
Market Cap in USD | 7m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2001-01-02 |
AEMD Stock Ratings
Growth 5y | -82.2% |
Fundamental | 1.12% |
Dividend | 0.0% |
Rel. Strength Industry | -74.5 |
Analysts | 3.5/5 |
Fair Price Momentum | 0.24 USD |
Fair Price DCF | - |
AEMD Dividends
No Dividends PaidAEMD Growth Ratios
Growth Correlation 3m | -9.8% |
Growth Correlation 12m | -26.9% |
Growth Correlation 5y | -88.9% |
CAGR 5y | -49.02% |
CAGR/Max DD 5y | -0.49 |
Sharpe Ratio 12m | -1.71 |
Alpha | -83.61 |
Beta | 1.20 |
Volatility | 156.30% |
Current Volume | 186.2k |
Average Volume 20d | 246.9k |
As of March 14, 2025, the stock is trading at USD 0.42 with a total of 186,199 shares traded.
Over the past week, the price has changed by -8.19%, over one month by -33.06%, over three months by +17.82% and over the past year by -74.55%.
Neither. Based on ValueRay Fundamental Analyses, Aethlon Medical is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 1.12 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AEMD as of March 2025 is 0.24. This means that AEMD is currently overvalued and has a potential downside of -42.86%.
Aethlon Medical has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold AEMD.
- Strong Buy: 0
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AEMD Aethlon Medical will be worth about 0.3 in March 2026. The stock is currently trading at 0.42. This means that the stock has a potential downside of -38.1%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 3.9 | 823.8% |
Analysts Target Price | 3.9 | 816.7% |
ValueRay Target Price | 0.3 | -38.1% |